ArticleFrontiers in genetics2022
Governing biotechnology to provide safety and security and address ethical, legal, and social implications.
Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- CRISPR-Cas systems for enhancing chilling tolerance in rice: recent advances and future prospects.Biologia futura · 2026Review
- Article
- Confusion, communication, and consent: ELSI barriers to genomics-enhanced remediation in Alberta's oil sands.Frontiers in genetics · 2026Article
- Safe Meat, Smart Science: Biotechnology's Role in Antibiotic Residue Removal.Antibiotics (Basel, Switzerland) · 2025Review
- Building public trust and acceptance towards spray-on RNAi biopesticides: lessons from current ethical, legal and social discourses.GM crops & food · 2025Review
- The convergence of AI and synthetic biology: the looming deluge.npj biomedical innovations · 2025Article
- Iron oxide nanoparticles enhance alkaline stress resilience in bell pepper by modulating photosynthetic capacity, membrane integrity, carbohydrate metabolism, and cellular antioxidant defense.BMC plant biology · 2025Article
- Natural vs. genetically engineered microbiomes: understanding public attitudes for indoor applications and pathways for future engagement.Frontiers in genetics · 2025Article
- Public perceptions and support for introduced microbes to combat hospital-acquired infections and antimicrobial resistance.PloS one · 2025Article
- Advancements in genetic studies of mushrooms: a comprehensive review.World journal of microbiology & biotechnology · 2024Review
- The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2024Article
- Navigating biosafety regulatory frameworks for genetic engineering in Africa: a focus on genome editing and gene drive technologies.Frontiers in bioengineering and biotechnology · 2024Article
- Bridging biosafety and biosecurity gaps: DURC and ePPP policy insights from U.S. institutions.Frontiers in bioengineering and biotechnology · 2024Article
- Taking the temperature of the United States public regarding microbiome engineering.Frontiers in public health · 2024Article
- Synthetic biology regulation in Europe: containment, release and beyond.Synthetic biology (Oxford, England) · 2023Review
- The African continent should consider a harmonized consultative and collaborative effort towards coordinated policy and regulatory guidelines across the fields of biotechnology.Frontiers in bioengineering and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of biotechnology has produced a wide variety of materials and products which are rapidly entering the commercial marketplace. While many developments promise revolutionary benefits, some of them pose uncertain or largely untested risks and may spur debate, consternation, and outrage from individuals and groups who may be affected by their development and use. In this paper we show that the success of any advanced genetic development and usage requires that the creators establish technical soundness, ensure safety and security, and transparently represent the product's ethical, legal, and social implications (ELSI). We further identify how failures to address ELSI can manifest as significant roadblocks to product acceptance and adoption and advocate for use of the "safety-by-design" governance philosophy. This approach requires addressing risk
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.